Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A squamous cell carcinoma that arises from the mucosal epithelial surface of the ethmoid, frontal, maxillary, or sphenoid sinus. Patients may present with nasal fullness, obstruction, and/or epistaxis.
Biomarker and diagnostic research for paranasal sinus squamous cell carcinoma has been reported in the published literature.
8 clinical trials registered, 4 recruiting. Interventions under study include drug therapy, procedural interventions, other interventions, and biologic therapy. Pipeline includes 4 PHASE2, 3 PHASE1, 1 NA. Research is primarily sponsored by academic and government institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT07156227](https://clinicaltrials.gov/study/NCT07156227) |
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 3:04 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma |
PHASE1 |
National Cancer Institute (NCI) |
RECRUITING |
[NCT06662058](https://clinicaltrials.gov/study/NCT06662058) | Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation | NA | Emory University | RECRUITING |
[NCT03493425](https://clinicaltrials.gov/study/NCT03493425) | Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery | PHASE2 | ECOG-ACRIN Cancer Research Group | UNKNOWN |
[NCT04576091](https://clinicaltrials.gov/study/NCT04576091) | Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer | PHASE1 | National Cancer Institute (NCI) | ACTIVE_NOT_RECRUITING |
[NCT05172245](https://clinicaltrials.gov/study/NCT05172245) | Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer | PHASE1 | National Cancer Institute (NCI) | RECRUITING |
134 publications have been identified in PubMed for paranasal sinus squamous cell carcinoma. Research spans Review / Meta-Analysis (20%), Epidemiology / Natural History (20%), and Case Report / Case Series (19%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 27 | 20% |
Disease patterns and progression | 27 | 20% |
Patient case studies | 26 | 19% |
Clinical study results | 20 | 15% |
Testing and diagnosis research | 18 | 13% |
Laboratory research | 14 | 10% |
Other research | 1 | 1% |
New treatment approaches | 1 | 1% |
Duprez F (2026). [PMID: 42038372](https://pubmed.ncbi.nlm.nih.gov/42038372/). *Front Oncol*. [Review / Meta-Analysis]
Lépine C (2026). [PMID: 41702743](https://pubmed.ncbi.nlm.nih.gov/41702743/). *Eur Ann Otorhinolaryngol Head Neck Dis*. [Review / Meta-Analysis]
Cracchiolo JR (2026). [PMID: 41702157](https://pubmed.ncbi.nlm.nih.gov/41702157/). *Oral Oncol*. [Review / Meta-Analysis]
Kumar P (2026). [PMID: 41032633](https://pubmed.ncbi.nlm.nih.gov/41032633/). *Int J Surg Pathol*. [Epidemiology / Natural History]
Yu AJ (2026). [PMID: 41525427](https://pubmed.ncbi.nlm.nih.gov/41525427/). *Am J Rhinol Allergy*. [Diagnostic / Biomarker]
Kuga R (2026). [PMID: 41731210](https://pubmed.ncbi.nlm.nih.gov/41731210/). *Hum Cell*. [Case Report / Case Series]
Hassan CH (2026). [PMID: 41720745](https://pubmed.ncbi.nlm.nih.gov/41720745/). *Eur Ann Otorhinolaryngol Head Neck Dis*. [Review / Meta-Analysis]
Zhong CY (2026). [PMID: 41735419](https://pubmed.ncbi.nlm.nih.gov/41735419/). *Sci Rep*. [Diagnostic / Biomarker]
Bell D (2026). [PMID: 40621801](https://pubmed.ncbi.nlm.nih.gov/40621801/). *Head & neck*. [Basic Science / Preclinical]
Brame L (2026). [PMID: 41876393](https://pubmed.ncbi.nlm.nih.gov/41876393/). *Cancer Med*. [Epidemiology / Natural History]